P Alan Barber1, Teddy Y Wu1, Annemarei Ranta2. 1. From the Department of Neurology (P.A.B.), Auckland City Hospital; Department of Neurology (T.Y.W.), Christchurch Hospital; Department of Neurology (A.R.), Wellington Regional Hospital; and Department of Medicine (A.R.), University of Otago, Wellington, New Zealand. 2. From the Department of Neurology (P.A.B.), Auckland City Hospital; Department of Neurology (T.Y.W.), Christchurch Hospital; Department of Neurology (A.R.), Wellington Regional Hospital; and Department of Medicine (A.R.), University of Otago, Wellington, New Zealand. anna.ranta@otago.ac.nz.
Abstract
OBJECTIVE: To assess the frequency and utilization trends of dabigatran reversal with idarucizumab and compare associated complications, outcomes, and door-to-needle times to those of patients not exposed to idarucizumab in a nationwide cohort of thrombolyzed patients over a 24-month period. METHODS: This is an observational cohort study of all New Zealand patients with stroke treated with stroke reperfusion entered into a mandatory online national registry. Each hospital records data including patient demographics, treatment delays, complications, 7-day outcomes, and idarucizumab use. RESULTS: Between 1 January 2017 and 31 December 2018, 1,336 patients received thrombolysis. Fifty-one patients received idarucizumab prior to thrombolysis (median [interquartile range] age 73 [57-83] years): 8 (1.3%) in 2017 and 43 (6%) in 2018 (p < 0.001). Over the same 24-month period, 386 patients had stroke clot retrieval, of whom 8 (2.1%) were first treated with idarucizumab. Idarucizumab-treated patients had slower door-to-needle times (83 [54-110] minutes vs 61 [43-85] minutes, p = 0.0006). Symptomatic intracerebral hemorrhage occurred in 2 (3.9%) of the idarucizumab-treated patients and 49 (3.8%) of the other thrombolyzed patients (p = 0.97). None of the idarucizumab-treated patients had significant thrombotic complications. At 7 days, 3 (5.9%) idarucizumab-treated and 101 (7.9%) of the other thrombolyzed patients had died (p = 0.61). CONCLUSION: Idarucizumab was used in 6% of all thrombolyzed patients in a national cohort during 2018, up from 1.3% in 2017. Idarucizumab appeared to be safe with similar clinical outcomes to routinely managed patients, despite a 22-minute door-to-needle time delay. Idarucizumab can facilitate thrombolysis in patients with stroke taking dabigatran. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that idarucizumab use is associated with similar early post-thrombolysis outcomes compared with patients not exposed to this drug.
OBJECTIVE: To assess the frequency and utilization trends of dabigatran reversal with idarucizumab and compare associated complications, outcomes, and door-to-needle times to those of patients not exposed to idarucizumab in a nationwide cohort of thrombolyzed patients over a 24-month period. METHODS: This is an observational cohort study of all New Zealand patients with stroke treated with stroke reperfusion entered into a mandatory online national registry. Each hospital records data including patient demographics, treatment delays, complications, 7-day outcomes, and idarucizumab use. RESULTS: Between 1 January 2017 and 31 December 2018, 1,336 patients received thrombolysis. Fifty-one patients received idarucizumab prior to thrombolysis (median [interquartile range] age 73 [57-83] years): 8 (1.3%) in 2017 and 43 (6%) in 2018 (p < 0.001). Over the same 24-month period, 386 patients had stroke clot retrieval, of whom 8 (2.1%) were first treated with idarucizumab. Idarucizumab-treated patients had slower door-to-needle times (83 [54-110] minutes vs 61 [43-85] minutes, p = 0.0006). Symptomatic intracerebral hemorrhage occurred in 2 (3.9%) of the idarucizumab-treated patients and 49 (3.8%) of the other thrombolyzed patients (p = 0.97). None of the idarucizumab-treated patients had significant thrombotic complications. At 7 days, 3 (5.9%) idarucizumab-treated and 101 (7.9%) of the other thrombolyzed patients had died (p = 0.61). CONCLUSION:Idarucizumab was used in 6% of all thrombolyzed patients in a national cohort during 2018, up from 1.3% in 2017. Idarucizumab appeared to be safe with similar clinical outcomes to routinely managed patients, despite a 22-minute door-to-needle time delay. Idarucizumab can facilitate thrombolysis in patients with stroke taking dabigatran. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that idarucizumab use is associated with similar early post-thrombolysis outcomes compared with patients not exposed to this drug.
Authors: Eivind Berge; William Whiteley; Heinrich Audebert; Gian Marco De Marchis; Ana Catarina Fonseca; Chiara Padiglioni; Natalia Pérez de la Ossa; Daniel Strbian; Georgios Tsivgoulis; Guillaume Turc Journal: Eur Stroke J Date: 2021-02-19
Authors: Duncan Wilson; Teddy Y Wu; David J Seiffge; Thomas Meinel; Jan Christoph Purrucker; Johannes Kaesmacher; Urs Fischer Journal: J Neurol Neurosurg Psychiatry Date: 2021-02-04 Impact factor: 10.154
Authors: Thomas R Meinel; Mattia Branca; Gian Marco De Marchis; Krassen Nedeltchev; Timo Kahles; Leo Bonati; Marcel Arnold; Mirjam R Heldner; Simon Jung; Emmanuel Carrera; Elisabeth Dirren; Patrik Michel; Davide Strambo; Carlo W Cereda; Giovanni Bianco; Georg Kägi; Jochen Vehoff; Mira Katan; Manuel Bolognese; Roland Backhaus; Stephan Salmen; Sylvan Albert; Friedrich Medlin; Christian Berger; Ludwig Schelosky; Susanne Renaud; Julien Niederhauser; Christophe Bonvin; Michael Schaerer; Marie-Luise Mono; Biljana Rodic; Alexander A Tarnutzer; Pasquale Mordasini; Jan Gralla; Johannes Kaesmacher; Stefan Engelter; Urs Fischer; David J Seiffge Journal: Ann Neurol Date: 2020-10-17 Impact factor: 10.422
Authors: Jordi Kühne Escolà; Simon Nagel; Verena Panitz; Tilman Reiff; Alexander Gutschalk; Christoph Gumbinger; Jan Christoph Purrucker Journal: J Clin Med Date: 2021-05-02 Impact factor: 4.241
Authors: Shadi Yaghi; Eva Mistry; Adam de Havenon; Christopher R Leon Guerrero; Amre Nouh; Ava L Liberman; James Giles; Angela Liu; Muhammad Nagy; Ashutosh Kaushal; Idrees Azher; Brian Mac Grory; Hiba Fakhri; Kiersten Brown Espaillat; Syed Daniyal Asad; Hemanth Pasupuleti; Heather Martin; Jose Tan; Manivannan Veerasamy; Charles Esenwa; Natalie Cheng; Khadean Moncrieffe; Iman Moeini-Naghani; Mithilesh Siddu; Erica Scher; Tushar Trivedi; Teddy Wu; Muhib Khan; Salah Keyrouz; Karen Furie; Nils Henninger Journal: J Am Heart Assoc Date: 2021-07-29 Impact factor: 5.501